

# Contents

|   |           |
|---|-----------|
| Foreword .....  | vii       |
| New Zealand foreword.....   | viii      |
| Preface .....   | ix        |
| Executive summary.....  | xi        |
| Introduction .....  | xiii      |
| Summary of clinical practice recommendations .....  | xix       |
| <b>1 Prevention .....</b>   | <b>1</b>  |
| <b>2 Population-based whole-body skin screening for melanoma.....</b>   | <b>5</b>  |
| 2.1 Proportion of population undergoing whole-body skin examination.....  | 5         |
| 2.2 Accuracy of whole-body skin examination by health professionals .....                                       | 6         |
| 2.3 Thickness of melanoma detected through skin screening by health professionals .....                         | 7         |
| 2.4 Cost-effectiveness of population-based skin screening by health professionals.....                          | 8         |
| 2.5 Effectiveness of whole-body skin examination by health professionals<br>in reducing melanoma mortality..... | 9         |
| <b>3 Identification and management of high-risk individuals.....</b>  | <b>15</b> |
| 3.1 Strongest predictors of future cutaneous melanoma .....   | 15        |
| 3.2 Baseline risks due to age and sex .....   | 15        |
| 3.3 Previous melanoma or other skin cancer.....   | 16        |
| 3.4 Melanocytic naevi .....   | 16        |
| 3.5 Skin and hair colour, skin phototype and freckling .....  | 16        |
| 3.6 Sun exposure and its surrogates .....   | 16        |
| 3.7 Family history of melanoma .....  | 17        |
| 3.8 Management of high-risk individuals .....   | 18        |
| 3.9 Good practice point.....  | 18        |
| 3.10 Genetic risk factors and testing .....   | 19        |
| <b>4 Classification and staging of melanoma .....</b>   | <b>23</b> |
| 4.1 Extract from AJCC Cancer Staging Manual, 6th edition, 2002.....   | 24        |

|           |  |           |
|-----------|--|-----------|
| <b>5</b>  | <b>Clinical diagnosis</b> .....  | <b>27</b> |
| 5.1       | How patients detect melanoma .....   | 27        |
| 5.2       | How doctors detect melanoma.....   | 27        |
| 5.3       | Clinical melanoma subtypes .....   | 28        |
| 5.4       | Good practice points .....   | 29        |
| 5.5       | Identification of the high-risk patient for prospective surveillance for melanoma..... | 29        |
| 5.6       | Evidence-based assessment of aids to the clinical diagnosis of melanoma .....          | 29        |
| 5.7       | Total body photography for early melanoma diagnosis in high-risk subjects .....        | 30        |
| <b>6</b>  | <b>Biopsy</b> .....  | <b>35</b> |
| 6.1       | Complete excisional biopsies .....   | 35        |
| 6.2       | Partial biopsies .....   | 35        |
| 6.3       | Alternative approaches.....  | 37        |
| 6.4       | Good practice point.....   | 38        |
| <b>7</b>  | <b>Histopathological reporting of cutaneous melanoma</b> .....                         | <b>41</b> |
| 7.1       | Comments on the histopathological reporting of melanoma .....                          | 42        |
| 7.2       | Pathology request form.....  | 44        |
| 7.3       | Recommended terminology and synonyms for cutaneous melanoma .....                      | 46        |
| 7.4       | Format of the report .....   | 47        |
| 7.5       | Pathology report on sentinel and non-sentinel lymph nodes .....                        | 50        |
| 7.6       | Pathology report on lymph node dissection specimens .....                              | 51        |
| <b>8</b>  | <b>Appropriate investigations</b> .....  | <b>55</b> |
| 8.1       | Investigations following the diagnosis of primary melanoma .....                       | 55        |
| 8.2       | Investigations following the diagnosis of locoregional disease.....                    | 57        |
| 8.3       | Investigations following the diagnosis of metastatic melanoma.....                     | 59        |
| <b>9</b>  | <b>Congenital melanocytic naevi</b> .....  | <b>63</b> |
| 9.1       | Risk of melanoma in patients with congenital melanocytic naevi.....                    | 63        |
| 9.2       | Approach to management of patients with congenital melanocytic naevi .....             | 64        |
| 9.3       | Good practice points .....   | 66        |
| <b>10</b> | <b>Lentigo maligna</b> .....   | <b>69</b> |
| <b>11</b> | <b>Treatment of primary melanoma</b> .....   | <b>73</b> |
| 11.1      | Review of the evidence .....   | 73        |
| 11.2      | Good practice points .....   | 75        |
| <b>12</b> | <b>Management of regional lymph nodes in melanoma</b> .....                            | <b>79</b> |
| 12.1      | Sentinel lymph node biopsy .....   | 79        |
| 12.2      | Therapeutic lymph node dissection.....   | 82        |
| 12.3      | Good practice points .....   | 84        |

|           |  |            |
|-----------|--|------------|
| <b>13</b> | <b>Management of locoregionally recurrent melanoma</b> .....   | <b>87</b>  |
| 13.1      | Persistent melanoma .....  | 87         |
| 13.2      | Local metastasis, in transit metastasis and satellitosis.....  | 88         |
| 13.3      | Regional lymph nodes .....   | 90         |
| <b>14</b> | <b>Adjuvant systemic therapy of melanoma</b> .....   | <b>93</b>  |
| <b>15</b> | <b>Treatment of disseminated melanoma</b> .....  | <b>95</b>  |
| 15.1      | Brain metastases.....  | 96         |
| 15.2      | Surgery .....  | 96         |
| <b>16</b> | <b>Psychosocial issues in melanoma</b> .....   | <b>101</b> |
| 16.1      | Effect of psychosocial interventions in patients with melanoma .....   | 101        |
| 16.2      | Communication strategies to reduce psychosocial morbidity<br>and unmet needs in patients with melanoma ..... | 105        |
| 16.3      | Influence of patients' psychosocial characteristics on prognosis.....  | 106        |
| 16.4      | Influence of psychosocial interventions on prognosis .....   | 108        |
| <b>17</b> | <b>Palliative care in melanoma</b> .....   | <b>113</b> |
| 17.1      | Timing of referral for palliative care .....   | 114        |
| 17.2      | Patients and families who benefit from referral to specialist palliative care.....                           | 115        |
| <b>18</b> | <b>Multidisciplinary care of melanoma</b> .....  | <b>119</b> |
| 18.1      | Review of the evidence .....   | 119        |
| <b>19</b> | <b>Follow-up</b> .....   | <b>121</b> |
| 19.1      | Introduction.....  | 121        |
| 19.2      | Undertaking follow-up.....   | 121        |
| 19.3      | Follow-up intervals and tests .....  | 122        |
| 19.4      | Value of follow-up .....   | 123        |
| <b>20</b> | <b>Clinical trials</b> .....   | <b>127</b> |
| 20.1      | Good practice point.....   | 128        |
| <b>21</b> | <b>Treatment of desmoplastic melanoma</b> .....  | <b>129</b> |
| <b>22</b> | <b>Mucosal melanoma</b> .....  | <b>131</b> |
| 22.1      | Melanoma of the anorectal region .....   | 131        |
| 22.2      | Mucosal melanoma of the head and neck .....  | 134        |
| 22.3      | Melanoma of the oesophagus.....  | 135        |
| 22.4      | Melanoma of the male genito-urinary tract .....  | 135        |
| 22.5      | Vulval melanoma.....   | 136        |
| 22.6      | Vaginal melanoma .....   | 137        |
| 22.7      | Good practice points .....   | 138        |

|           |  |            |
|-----------|--|------------|
| <b>23</b> | <b>Occult melanoma</b> .....   | <b>141</b> |
| <b>24</b> | <b>Ocular melanoma</b> .....   | <b>143</b> |
| <b>25</b> | <b>Melanoma in children</b> .....  | <b>145</b> |
| 25.1      | Diagnosis .....  | 145        |
| 25.2      | Treatment and survival .....   | 146        |
| <b>26</b> | <b>Pregnancy and melanoma (including hormone replacement therapy and oral contraceptives)</b> .....        | <b>151</b> |
| 26.1      | Naevi and pregnancy .....  | 151        |
| 26.2      | Melanoma and pregnancy .....   | 151        |
| 26.3      | Pregnancy after the diagnosis of melanoma .....  | 152        |
| 26.4      | Treatment of melanoma during pregnancy .....   | 152        |
| 26.5      | Melanoma and hormone replacement therapy and the oral contraceptive pill .....                             | 153        |
| <b>27</b> | <b>Prognostic factors and survival outcomes in cutaneous melanoma</b> .....                                | <b>157</b> |
| 27.1      | Prognostic factors .....   | 157        |
| 27.2      | Survival outcomes .....  | 159        |
| <b>28</b> | <b>Complementary and alternative medicine</b> .....  | <b>163</b> |
| 28.1      | CAM – what patients find worthwhile .....  | 164        |
| 28.2      | Comparing CAM and conventional therapies for melanoma .....  | 165        |
| 28.3      | Value for money and CAM therapies .....  | 166        |
| <b>29</b> | <b>Melanoma in specific populations in Australia</b> .....   | <b>169</b> |
| 29.1      | Melanoma in non-Caucasians .....   | 169        |
| 29.2      | Good practice point .....  | 171        |
| <b>30</b> | <b>Melanoma in Māori and melanoma in Pacific peoples in New Zealand</b> .....                              | <b>173</b> |
| 30.1      | Melanoma in Māori .....  | 173        |
| 30.2      | Good practice points .....   | 174        |
| 30.3      | Melanoma in Pacific peoples in New Zealand .....   | 175        |
| 30.4      | Good practice points .....   | 176        |
|           | <b>Appendices</b> .....  | <b>179</b> |
| 1:        | Medico-legal considerations .....  | 180        |
| 2:        | Guideline development process .....  | 182        |
| 3:        | Working party membership and contributors to guidelines and public consultation submissions received ..... | 190        |
| 4:        | Dermoscopy versus naked eye examination for the diagnosis of melanoma .....                                | 196        |
| 5:        | Recommended terminology and synonyms for cutaneous melanoma .....  | 203        |
| 6:        | New Zealand palliative care definition .....   | 204        |

|                                 |     |
|---------------------------------|-----|
| Abbreviations and glossary..... | 209 |
| Index .....                     | 217 |

## List of tables

|    |   |     |
|----|---|-----|
| 1  | Trends in five-year relative survival from melanoma diagnosed in New South Wales, Australia, from 1980 to 1998.....   | xvi |
| 2  | Designations of levels of evidence according to type of research question.....  | xx  |
| 3  | Melanoma TNM classification.....  | 25  |
| 4  | Stage groupings for cutaneous melanoma .....  | 26  |
| 5  | The histological features of persistent primary melanoma versus local metastasis of melanoma.....   | 45  |
| 6  | Studies comparing Abdomino-pelvic resection and sphincter preserving wide local excision for patients with localised anal melanoma (more than 30 patients and published since 1990) ..... | 134 |
| 7  | Prognostic factors in melanoma .....  | 158 |
| 8  | Survival rates for melanoma TNM and staging categories.....   | 159 |
| A1 | Claims – National Medical Defence Organisation (1990–2005) .....  | 180 |
| A2 | Designations of levels of evidence according to type of research question.....  | 186 |

## List of figures

|   |  |     |
|---|--|-----|
| 1 | Trends in the age-standardised incidence rates (ASR) of melanoma in Australia and New Zealand..... | xiv |
| 2 | Trends in the age-standardised mortality rates (ASR) of melanoma in Australia and New Zealand..... | xv  |
| 3 | Distribution of lymph node metastases for melanomas 1.2–3.5mm thick .....                          | 81  |